# NIH Reporter #3R34AI198088-01S6

Aggressive antipyretics for neuroprotection and mortality reduction in CNS malaria: A Randomized-Controlled Trial

**Recipient:** University of Rochester

**Award Amount:** $6,995.00
**Ceiling:** $6,995.00

**Awarded:** September 15, 2026

**Identifier:** 3R34AI198088-01S6

A phase III randomized controlled trial funded by NIH to test aggressive antipyretic therapy for reducing mortality and neurological morbidity in children with CNS malaria.

### Description

This project involves a phase III randomized controlled trial to evaluate the efficacy of adjunctive aggressive antipyretic therapy in children with CNS malaria, aiming to reduce mortality and neurological morbidity. The project is funded by the NIH and involves international collaboration in Malawi, Zambia, and the Democratic Republic of Congo.

[View original record](https://reporter.nih.gov/search/IgE1H2ioLUOz0qmA4MDg0Q/project-details/11604407)